Boston Children's Hospital is monitoring the developing situation with lead contamination in some Boston Public Schools. Please contact your primary care physician if you have any concerns about your child.
Boston Children’s Hospital está monitoreando la situación de la contaminación por plomo en algunas escuelas públicas de Boston. Por favor, póngase en contacto con su médico primario si usted tiene alguna preocupación acerca de su hijo.
Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Children with hematologic malignancies, including leukemia and lymphoma, are treated through the Hematologic Malignancy Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children's Hospital. In addition to treating lymphomas and leukemias, we treat the primary types of histiocytosis, which is not a form of cancer but shares some common characteristics and is often treated using some of the same therapies.
Our multidisciplinary approach to care ensures thoughtful discussion of every treatment decision and individualized care plans for each patient. Our team integrates expertise from the following specialists:
Our center played a key role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90 percent for pediatric acute lymphoblastic leukemia (ALL). The program sees more than 125 newly diagnosed patients with leukemia and lymphoma annually and continues to lead high-impact clinical trials designed to increase cure rates, decrease treatment-related toxicities and improve care for long-term survivors. In addition, our program treats children and adolescents with other conditions, including post-transplant lymphoproliferative disorder, hemophagocytic lymphohistiocytosis (HLH), a life-threatening condition caused by immune dysregulation, primarily of histiocytes and lymphocytes, and Langerhans cell histiocytosis (LCH), which is a cancer-like condition and may involve treatment with chemotherapy.
Learn more about the Hematologic Malignancy Center, which includes our:
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”